Icon times
Sun Pharma Q1 FY22 Conference Call Highlights - Sun Pharma Financial Results | Invest Yadnya

Sun Pharma Q1 FY22 Conference Call Highlights

Published on 02 August 2021 .Views 17 .Comments 0
Share On

Financial Highlights

Standalone Business

  • Revenue from operations according to Sun Pharma annual report, stood at 3326 crores rising 12% YOY & 5% QOQ of the Sun Pharma mutual fund.

  • Operating Expenses of Sun Pharma share price also rose to 2836 crores rising 23% YOY & 14% QOQ as of Sun Pharma financial report.

  • The EBITDA of Sun Pharma financial result stood at 689 crores declining 7% YOY & 3% QOQ according to Sun Pharma fundamental analysis.

  • EBITDA of Sun Pharma fundamental Margin stood at 21% declining 4% YOY & 2%QOQ as of Sun Pharma technical analysis.

  • PAT of Sun Pharma analysis stood at 419 crores declining 21% YOY but rising 28% QOQ according to Sun Pharma technical chart.

  • PAT margin stood at 13% declining 5% YOY but rising 3% QOQ

Consolidated Business

  • Revenue from operations as of Sun Pharma share price history stood at 9719 crores rising 28% YOY & 14% QOQ

  • Operating Expenses also rose to 6978 crores rising 19% YOY & 7.7% QOQ

  • EBITDA stood at 2974 crores rising 49% YOY & 38% QOQ

  • EBITDA Margin stood at 31% rising 5% YOY & 6%QOQ

  • PAT stood at 1444 crores rising 187% YOY & 61% QOQ

  • PAT margin stood at 15% rising 37% YOY& 5% QOQ

Note: YOY PAT & PAT margin was negative due to one-off events

Business Highlights

  • Results were driven by robust core business growth, low base, and some sale of Covid products

  • India contributed 34% of total revenue. Covid products contributed 8-10% of India sales. The sale of branded formulations in India for Q1FY22 was at Rs. 33,084 million, up by 39% over Q1 last year, and accounting for 34% of total sales.

  • Sun Pharma is ranked No. 1 and holds above 8.0% market share in the over Rs. 1,594 Billion Indian pharmaceutical market as per AIOCD AWACS MAT June-2021 report. For Q1FY22, the company launched 13 new products in the Indian market.

  • The company launched 13 new products in the Indian market in Q1FY22

  • The US was 29% of total sales, driven by growth in specialty business

  • The management witnessed an uptick in sales of ILumya, Ceqa, etc, which countered the loss in business of Absorica

  • Following specialty products are under development ILumya for Psoriatic Arthritis

    • GLP 1R for diabetes

    • SCD-044 for Atopic Dermatitis

  • Recently licensed Winlevi (topical treatment for acne) will add to Derma portfolio and the management expects to launch the same in the US by December 2021

  • Patients doctor visit in the US is still below pre-Covid levels but the situation is getting normalized.

  • Emerging Markets: Sales in Emerging Markets were at US$ 218 million for Q1, a growth of 25% over Q1 last year. Overall sales in Emerging Markets accounted for about 17% of total consolidated sales for the quarter.

  • Rest of World Markets: Formulation sales in Rest of World (ROW) markets, excluding US and Emerging Markets, were US$ 185 million in Q1FY22, up by 35% over Q1 last year and accounted for approximately 14% of total consolidated sales.

  • Active Pharmaceutical Ingredients (API): Strategic strength For Q1FY22, external sales of API were at Rs. 5,149 million, down 7% over Q1 last year. API business imparts benefits of vertical integration and continuity of supply chain for the formulations business.

  • Global specialty revenue for Q1FY22: US$148 million. The management guided for double-digit growth in specialty portfolio for FY22

  • Consolidated R&D investment for Q1FY22 was 592.6 crore compared to 420.6 million for Q1 last year. Specialty R&D was 26% of total R&D investment

  • Approved ANDAs: 505, approved NDAs: 53 filings: 86 ANDAs & 13 NDAs await US FDA approval, including 22 tentative approvals. Six approvals were received in Q1FY22

  • The company has repaid debt of about US$185 million in Q1FY22. Over the last five quarters, debt repaid was about US$765 million. The company is net cash positive (ex-Taro)

  • R&D Expenditure Breakup: 592.6 crores: Capital Exp:17.7 crores & Revenue 574.8 crores


Invest yadnya is one of the best websites for fundamental analysis of Indian stocks. They provide the best website for ready made portfolios in India. Invest Yadnya gives stock market books so that  anyone can invest in their website . They provide financial analysis best books and  free books on mutual funds  to their investors  . They have a special free stock screener India which gives  very exact and illustrated analysis of companies. Not only , ready made portfolio websites investors can also get information about financial advice services

There are  also various articles on different sectors like Hindustan Unilever, Tata Consultancy Services , Tata Power Company, Dixon Technologies, Bandhan Bank, HDFC Bank etc.

private article suscription area icon

You like to know more. We like that!

Please subscribe Model Portfolio Plan to get access of all premium model portfolio articles Only at Rs. 9,999.00/Year.

Please login to view this free article.

This blog is available only for logged in users, please register and get access to view this article.

Recently Uploaded

premium Premium
free Free
Chat on WhatsApp
Caret UP Arrow
InvestYadnya Support
Typically replies in minutes
InvestYadnya Support
Hi there
Welcome to InvestYadnya.
We are available to assist you on WhatsApp.
Please click on the button below to chat with us.
(10 AM to 7 PM IST)
Chat with InvestYadnya